MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.

Amgen has initiated two “critical” late-stage trials for its experimental weight loss injection, MariTide. MariTide is a ...

MariTide only needs to be taken once a month, and it's helped people lose up to 20% of their weight. Shares of this biotech are priced at a much lower premium than top GLP-1 drugmaker Eli Lilly.

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

Amgen on Wednesday said it has started two critical late-stage trials for its experimental weight loss injection MariTide, another step in its bid to enter the booming obesity drug market. " ...

But MariTide, which is Amgen's GLP-1 drug, only needs to be taken once a month. That can make it easier to stay on top of treatments. It may also result in fewer side effects, which is a key ...